Swoop® Portable MR Imaging® System

The Hyperfine, Inc. Swoop® Portable MR Imaging® System leverages ultra-low field magnetic resonance imaging to provide diagnostic images of the head, serving as a practical solution when full diagnostic examinations are not clinically feasible. Its scientific basis involves advanced reconstruction validation and rigorous non-clinical performance testing to ensure improved image quality and diagnostic consistency compared to predicate devices, enabling broader access to critical neuroimaging.

The Hyperfine, Inc. Swoop® Portable MR Imaging® System has recently received a determination of substantial equivalence (K251276) to existing legally marketed devices, clearing the path for its commercialization. This regulatory approval mandates compliance with general controls provisions, including registration, device listing, good manufacturing practices, and specific labeling requirements, along with adherence to quality systems, medical device reporting, and Unique Device Identification (UDI) regulations. The Swoop® system is an innovative portable, ultra-low field magnetic resonance imaging device specifically engineered to capture images of the internal structure of the head. Its primary purpose is to furnish diagnostic information in situations where a full, conventional diagnostic examination is not clinically feasible. Designed for prescription use within professional healthcare facilities, it serves both adult and pediatric patients across all age groups. The device's substantial equivalence was underpinned by comprehensive non-clinical performance testing, which encompassed software verification, detailed image performance evaluation, cybersecurity assessments, and advanced reconstruction validation, collectively demonstrating enhanced image quality and consistent diagnostic capability when benchmarked against a predicate device.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the 'ultra-low field' technology specifically compare to conventional MRI in terms of spatial resolution and signal-to-noise ratio for various intracranial pathologies?; What are the specific clinical scenarios where a 'full diagnostic examination is not clinically practical,' and what data support the Swoop system's effectiveness in these particular settings?; Beyond improved image quality, what quantitative metrics or specific diagnostic tasks were used to assess 'diagnostic consistency' compared to predicate devices, and across what range of patient conditions?; What are the reported practical considerations for deployment, maintenance, and data management of the Swoop system in diverse professional healthcare facilities, especially regarding its portability?; Could the advanced reconstruction validation and software improvements enable the Swoop system to evolve towards higher diagnostic capabilities or new indications in the future?